Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm3 (ACTG 175)

Journal of Infectious Diseases

Volumn 177, Issue 3, 1998, Pages 617-624

  Lathey, Janet L ^a   Hughes, Michael D ^c   Fiscus, Susan A ^c   Pi, Timothy ^c   Brooks Jackson, J ^c   Rasheed, Suraiya ^c   Elbeik, Tarek ^c   Reichman, Richard ^c   Japour, Anthony ^b   D'Aquila, Richard T ^c   Scott, Walter ^c   Griffith, Brigitte P ^c   Hammer, Scott M ^c   Katzenstein, David A ^c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b ABBOTT LABORATORIES   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GAG PROTEIN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SYNCYTIUM; T LYMPHOCYTE SUBPOPULATION; VIROLOGY; VIRUS REPLICATION;

EID: 17344371054     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514250     Document Type: Article

References (25)

1. + lymphocyte counts and the risk of progression. N Engl J Med 1996;334:426-31.
2. Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 1989;321:1621-5.
3. Coombs RW, Collier AC, Allain JP, et al. Plasma viremia in human immunodeficiency virus infection. N Engl J Med 1989;321:1621-5.
4. Piatak M, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993;259:1749-54.
5. Hammer S, Crumpacker C, D'Aquila R, et al. Use of virologie assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group virology committee. J Clin Microbiol 1993;31:2557-64.
6. Lin HJ, Myers LE, Yen-Lieberman B, et al. Multicenter evaluation of quantitative methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis 1994;170:553-62.
7. Yen-Lieberman B, Brambilla D, Jackson B, et al. Evaluation of a quality assurance program for quantitation of human immunodeficiency virus 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories. J Clin Microbiol 1996;34:2695-701.
8. Fiscus SA, DeGruttola V, Gupta P, et al. Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial. J Infect Dis 1995;17:305-11.
9. Cohen OJ, Pantaleo G, Holodniy M, et al. Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. Proc Natl Acad Sci USA 1995;92:6017-21.
10. Japour A, Fiscus S, Arduino JM, et al. Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J Clin Microbiol 1994;32:2291-4.
11. + cell depletion and progression to AIDS. Ann Intern Med 1993;118:681-8.
12. Tersmette M, Lange JMA, de Goode REY, et al. Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet 1989;1:983-5.
13. Richman DD, Bozzette SA. The impact of syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994;169:968-74.
14. Kozal MJ, Shafer RW, Winters MA, et al. HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients. J Acquir Immune Defic Syndr Hum Retrovirol 1994;7:832-8.
15. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
16. Katzenstein DA, Hammer SM, Hughes MD, et al. The relationship of virologie and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1091-8.
17. US Department of Health and Human Services. ACTG virology manual for HIV laboratories. Bethesda, MD: NIH, 1994;SIA-1-3; publication 94-3828.
18. Myers LE, McQuay LJ, Hollinger FB. Dilution assay statistics. J Clin Microbiol 1994;32:732-9.
19. Brambilla DJ, Bremer JW, Staes B, Michels C, Reichelderfer P, DAIDS-sponsored Virology Laboratories. Intra- and inter-assay variation in estimates of viral titers from quantitative microcultures. In: Program and abstracts: XI International Conference on AIDS (Vancouver, Canada). Vancouver: XI International Conference on AIDS Society, 1996;11: 330.
20. + lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 1997;126:929-38.
21. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
22. Phillips AN, Eron JJ, Bartlett JA, et al. HIV RNA levels and the development of clinical disease. AIDS 1996;10:859-65.
23. Coombs RW, Welles SL, Hooper C, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 1996; 174:704-12.
24. Galetto-Lacour A, Yerly S, Perneger TV, et al. Prognostic value of viremia in patients with long-standing human immunodeficiency virus infection. J Infect Dis 1995;173:1388-93.
25. Welles SL, Jackson AJ, Yen-Lieberman B, et al. Prognostic value of plasma human immunodeficiency virus type-1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. J Infect Dis 1996;174:696-703.